<PAGE>
ONYX PHARMACEUTICALS, INC.
3031 RESEARCH DRIVE
RICHMOND, CA 94806
April 19, 2000
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
450 Fifth Street, N.W.
Washington, DC 20549
Re: ONYX Pharmaceuticals, Inc.
CIK: 0001012140
Commission File No. 333-33322 Application for Withdrawal
Ladies and Gentlemen:
Pursuant to Rule 477(a) promulgated under the Securities Act of 1933, as
amended, ONYX Pharmaceuticals, Inc. (the "Registrant") hereby applies for an
order granting the immediate withdrawal of its Registration Statement on Form
S-3, together with all exhibits thereto, Commission File No. 333-33322
(collectively, the "Registration Statement"). The Registration Statement was
originally filed with the Securities and Exchange Commission (the "Commission")
on March 27, 2000.
Pursuant to the Registration Statement, the Registrant proposed to register
2,875,000 shares of its Common Stock, $0.001 par value per share, including the
underwriter's over allotment option (the "Shares"), for issuance to the public
with a proposed maximum offering price of $54,804,687. Based upon recent market
volatility and current market conditions particularly in the biotechnology
sector, the Registrant has determined not to pursue the public offering of
equity securities pursuant to the Registration Statement. No securities have
been sold under the Registration Statement.
Accordingly, we request an order granting the withdrawal of the Registration
Statement be issued by the Commission as soon as possible.
If you have any questions regarding the foregoing application for withdrawal,
please contact Robert L. Jones or Michael L. Weiner of Cooley Godward LLP, legal
counsel to the Registrant at (650) 843-5000.
Sincerely,
ONYX PHARMACEUTICALS, INC.
/s/ Hollings C. Renton
------------------------------------------
Hollings C. Renton
President and Chief Executive Officer
cc: Stuart Duty
Robert L. Jones
Michael L. Weiner
Douglas Fox
Marilyn Wortzman
